Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 316

1.

Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.

Benny Klimek ME, Aydogdu T, Link MJ, Pons M, Koniaris LG, Zimmers TA.

Biochem Biophys Res Commun. 2010 Jan 15;391(3):1548-54. doi: 10.1016/j.bbrc.2009.12.123. Epub 2009 Dec 28.

PMID:
20036643
2.

Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.

Murphy KT, Chee A, Gleeson BG, Naim T, Swiderski K, Koopman R, Lynch GS.

Am J Physiol Regul Integr Comp Physiol. 2011 Sep;301(3):R716-26. doi: 10.1152/ajpregu.00121.2011. Epub 2011 Jun 15.

3.

Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice.

Bonetto A, Penna F, Minero VG, Reffo P, Bonelli G, Baccino FM, Costelli P.

Curr Cancer Drug Targets. 2009 Aug;9(5):608-16. Epub 2009 Aug 1.

PMID:
19508174
4.

Myostatin gene inactivation prevents skeletal muscle wasting in cancer.

Gallot YS, Durieux AC, Castells J, Desgeorges MM, Vernus B, Plantureux L, Rémond D, Jahnke VE, Lefai E, Dardevet D, Nemoz G, Schaeffer L, Bonnieu A, Freyssenet DG.

Cancer Res. 2014 Dec 15;74(24):7344-56. doi: 10.1158/0008-5472.CAN-14-0057. Epub 2014 Oct 21.

5.

Induction of cachexia in mice by systemically administered myostatin.

Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, Lee SJ.

Science. 2002 May 24;296(5572):1486-8.

6.

Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice.

Nakatani M, Takehara Y, Sugino H, Matsumoto M, Hashimoto O, Hasegawa Y, Murakami T, Uezumi A, Takeda S, Noji S, Sunada Y, Tsuchida K.

FASEB J. 2008 Feb;22(2):477-87. Epub 2007 Sep 24.

PMID:
17893249
7.

Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells.

Argilés JM, Figueras M, Ametller E, Fuster G, Olivan M, de Oliveira CC, López-Soriano FJ, Isfort RJ, Busquets S.

Muscle Nerve. 2008 Feb;37(2):190-5.

PMID:
17912749
8.

Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.

Li Q, Kumar R, Underwood K, O'Connor AE, Loveland KL, Seehra JS, Matzuk MM.

Mol Hum Reprod. 2007 Sep;13(9):675-83. Epub 2007 Aug 18.

PMID:
17704537
9.

Muscle myostatin signalling is enhanced in experimental cancer cachexia.

Costelli P, Muscaritoli M, Bonetto A, Penna F, Reffo P, Bossola M, Bonelli G, Doglietto GB, Baccino FM, Rossi Fanelli F.

Eur J Clin Invest. 2008 Jul;38(7):531-8. doi: 10.1111/j.1365-2362.2008.01970.x.

PMID:
18578694
10.

The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virus-infected rhesus macaques.

O'Connell KE, Guo W, Serra C, Beck M, Wachtman L, Hoggatt A, Xia D, Pearson C, Knight H, O'Connell M, Miller AD, Westmoreland SV, Bhasin S.

FASEB J. 2015 Apr;29(4):1165-75. doi: 10.1096/fj.14-257543. Epub 2014 Dec 2.

11.

The possible role of myostatin in skeletal muscle atrophy and cachexia.

Jespersen J, Kjaer M, Schjerling P.

Scand J Med Sci Sports. 2006 Apr;16(2):74-82. Review.

PMID:
16533345
12.

Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy.

Lee YS, Lehar A, Sebald S, Liu M, Swaggart KA, Talbot CC Jr, Pytel P, Barton ER, McNally EM, Lee SJ.

Hum Mol Genet. 2015 Oct 15;24(20):5711-9. doi: 10.1093/hmg/ddv288. Epub 2015 Jul 23.

13.

Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.

Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, Lacey DL, Goldberg AL, Han HQ.

Cell. 2010 Aug 20;142(4):531-43. doi: 10.1016/j.cell.2010.07.011.

14.

Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.

Toledo M, Busquets S, Penna F, Zhou X, Marmonti E, Betancourt A, Massa D, López-Soriano FJ, Han HQ, Argilés JM.

Int J Cancer. 2016 Apr 15;138(8):2021-9. doi: 10.1002/ijc.29930. Epub 2015 Dec 9.

15.

Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.

Silva KA, Dong J, Dong Y, Dong Y, Schor N, Tweardy DJ, Zhang L, Mitch WE.

J Biol Chem. 2015 Apr 24;290(17):11177-87. doi: 10.1074/jbc.M115.641514. Epub 2015 Mar 18.

16.

Molecular, cellular and physiological investigation of myostatin propeptide-mediated muscle growth in adult mice.

Matsakas A, Foster K, Otto A, Macharia R, Elashry MI, Feist S, Graham I, Foster H, Yaworsky P, Walsh F, Dickson G, Patel K.

Neuromuscul Disord. 2009 Jul;19(7):489-99. doi: 10.1016/j.nmd.2009.06.367. Epub 2009 Jun 21.

PMID:
19541486
17.

Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice.

Llovera M, García-Martínez C, López-Soriano J, Carbó N, Agell N, López-Soriano FJ, Argiles JM.

Mol Cell Endocrinol. 1998 Jul 25;142(1-2):183-9.

PMID:
9783914
18.

Follistatin-derived peptide expression in muscle decreases adipose tissue mass and prevents hepatic steatosis.

Nakatani M, Kokubo M, Ohsawa Y, Sunada Y, Tsuchida K.

Am J Physiol Endocrinol Metab. 2011 Mar;300(3):E543-53. doi: 10.1152/ajpendo.00430.2010. Epub 2011 Jan 4.

19.

Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.

Hulmi JJ, Oliveira BM, Silvennoinen M, Hoogaars WM, Pasternack A, Kainulainen H, Ritvos O.

Am J Physiol Endocrinol Metab. 2013 Jul 15;305(2):E171-82. doi: 10.1152/ajpendo.00065.2013. Epub 2013 May 21.

20.

Embryonic overexpression of Galgt2 inhibits skeletal muscle growth via activation of myostatin signaling.

Chandraskeharan K, Martin PT.

Muscle Nerve. 2009 Jan;39(1):25-41. doi: 10.1002/mus.21198.

PMID:
19086062

Supplemental Content

Support Center